The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 20, 2021

Filed:

Mar. 02, 2017
Applicant:

Teva Pharmaceuticals Australia Pty Ltd, Macquarie Park, AU;

Inventors:

David S. Wilson, Jr., Freemont, CA (US);

Sarah L. Pogue, Freemont, CA (US);

Glen E. Mikesell, Pacifica, CA (US);

Tetsuya Taura, Palo Alto, CA (US);

Wouter Korver, Mountain View, CA (US);

Anthony G. Doyle, Drummoyne, AU;

Adam Clarke, Five Dock, AU;

Matthew Pollard, Dural, AU;

Stephen Tran, Strathfield South, AU;

Jack Tzu Chiao Lin, Redwood City, CA (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 14/54 (2006.01); C07K 14/565 (2006.01); C07K 14/57 (2006.01); C07K 16/10 (2006.01); A61K 47/64 (2017.01); C07K 14/56 (2006.01); C07K 16/46 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61K 47/642 (2017.08); C07K 14/5406 (2013.01); C07K 14/5412 (2013.01); C07K 14/56 (2013.01); C07K 14/565 (2013.01); C07K 14/57 (2013.01); C07K 16/1027 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); A61K 38/00 (2013.01); C07K 16/46 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C07K 2319/21 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01);
Abstract

The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.


Find Patent Forward Citations

Loading…